Eumycetoma (Fungal Mycetoma) Treatment & Management
- Author: George Turiansky, MD; Chief Editor: Dirk M Elston, MD more...
Treatment of eumycetoma remains problematic. Historically, the treatment of eumycetoma has included surgical treatment, medical treatment, or both. Combined surgical and medical treatment appears to be the management option of choice.
Antifungal therapy has variable results. Note the following:
- The sensitivity of organisms to antifungal drugs in vitro is not necessarily correlated with the in vivo response.
- Amphotericin B has minimal or no effect on eumycetoma organisms.
- Anecdotal reports of successful treatment with griseofulvin and dapsone exist.
- In one study, a case of eumycetoma due to M grisea initially responded to fluconazole 400 mg/d but worsened after the patient stopped the treatment. In the same report, 2 other cases due to M mycetomatis and P boydii had either slight improvement or only transient clinical improvement with fluconazole 200-400 mg/d for 3 months. These cases were classified as nonresponsive.
- Azole antifungal agents such as ketoconazole have some effectiveness. Mahgoub and Gumaa demonstrated that ketoconazole is effective in the treatment of eumycetoma caused by M mycetomatis. They treated 13 patients with oral ketoconazole 200-400 mg/d; 5 patients were cured, and 4 patients improved. The median treatment duration was 12.9 months, with a treatment range of 3-36 months. Cures were noted with the higher dosages of ketoconazole.
- A study by N'Diaye et al showed that high-dose terbinafine (500 mg bid) for 24-48 weeks was generally well tolerated. In the investigators' overall opinion at the end of the study, of 20 eumycetoma patients who completed the study, 5 patients were clinically cured and 11 were clinically improved.
Treatment in the past has included amputation of the affected limb or other radical surgery. Although surgical treatment alone results in recurrence rates as high as 80%, surgical resection with a wide surgical margin of uninfected tissue may be useful in early, small lesions without bony involvement. Surgical debulking together with oral antifungal treatment may be necessary with chronic extensive lesions.
Carter HV. On a new and striking form of fungus disease principally affecting the foot and prevailing endemically in many parts of India. Transactions of the Medical and Physical Society of Bombay. 1860. 6:104-42.
Carter HV. On mycetoma or the fungus disease of India. London, England: J & A Churchill; 1874.
Green WO Jr, Adams TE. Mycetoma in the United States; a review and report of seven additional cases. Am J Clin Pathol. 1964 Jul. 42:75-91. [Medline].
Abbott P. Mycetoma in the Sudan. Trans R Soc Trop Med Hyg. 1956 Jan. 50(1):11-24; discussion, 24-30. [Medline].
Werlinger KD, Yen Moore A. Eumycotic mycetoma caused by Cladophialophora bantiana in a patient with systemic lupus erythematosus. J Am Acad Dermatol. 2005 May. 52(5 Suppl 1):S114-7. [Medline].
Turiansky GW, Benson PM, Sperling LC, Sau P, Salkin IF, McGinnis MR, et al. Phialophora verrucosa: a new cause of mycetoma. J Am Acad Dermatol. 1995 Feb. 32(2 Pt 2):311-5. [Medline].
Mathuram Thiyagarajan U, Bagul A, Nicholson ML. A nodulo-cystic eumycetoma caused by Pyrenochaeta romeroi in a renal transplant recipient: A case report. J Med Case Reports. 2011 Sep 14. 5(1):460. [Medline]. [Full Text].
Ahmed AO, Desplaces N, Leonard P, Goldstein F, De Hoog S, Verbrugh H, et al. Molecular detection and identification of agents of eumycetoma: detailed report of two cases. J Clin Microbiol. 2003 Dec. 41(12):5813-6. [Medline].
Hemalata M, Prasad S, Venkatesh K, Niveditha SR, Kumar SA. Cytological diagnosis of actinomycosis and eumycetoma: a report of two cases. Diagn Cytopathol. 2010 Dec. 38(12):918-20. [Medline].
Gabhane SK, Gangane N, Anshu. Cytodiagnosis of eumycotic mycetoma: a case report. Acta Cytol. 2008 May-Jun. 52(3):354-6. [Medline].
Ahmed M, Sureka J, Chacko G, Eapen A. MRI findings in cranial eumycetoma. Indian J Radiol Imaging. 2011 Oct. 21(4):261-3. [Medline].
Mahgoub ES, Gumaa SA. Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii. Trans R Soc Trop Med Hyg. 1984. 78(3):376-9. [Medline].
Degavre B, Joujoux JM, Dandurand M, Guillot B. First report of mycetoma caused by Arthrographis kalrae: successful treatment with itraconazole. J Am Acad Dermatol. 1997 Aug. 37(2 Pt 2):318-20. [Medline].
Lee MW, Kim JC, Choi JS, Kim KH, Greer DL. Mycetoma caused by Acremonium falciforme: successful treatment with itraconazole. J Am Acad Dermatol. 1995 May. 32(5 Pt 2):897-900. [Medline].
Lacroix C, de Kerviler E, Morel P, Derouin F, Feuilhade de Chavin M. Madurella mycetomatis mycetoma treated successfully with oral voriconazole. Br J Dermatol. 2005 May. 152(5):1067-8. [Medline].
N'diaye B, Dieng MT, Perez A, Stockmeyer M, Bakshi R. Clinical efficacy and safety of oral terbinafine in fungal mycetoma. Int J Dermatol. 2006 Feb. 45(2):154-7. [Medline].
Diaz M, Negroni R, Montero-Gei F, Castro LG, Sampaio SA, Borelli D, et al. A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American Study Group. Clin Infect Dis. 1992 Mar. 14 Suppl 1:S68-76. [Medline].